Moclobemid Al (Moclobemide)

Moclobemide, the active ingredient in Moclobemid Al, is a monoamine oxidase inhibitor presented as an oral formulation for tablet use. It is prescribed for the treatment of major depressive disorder, dysthymia, and social anxiety disorder in adult patients. The reversible inhibition of MAO‑A increases neurotransmitter availability, helping to alleviate depressive and anxiety symptoms.

GNH USA supplies Moclobemid Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide through reliable logistics and regulatory support.

Moclobemide is indicated for several mood and anxiety conditions, acting through reversible inhibition of monoamine oxidase A to increase central serotonin, norepinephrine, and dopamine levels. - Major depressive disorder: reduces depressive symptoms, improves mood, and enhances daily functioning. - Dysthymia: alleviates chronic low‑grade depressive mood, supporting long‑term emotional stability. - Social anxiety disorder: decreases anxiety in social situations, facilitating better interpersonal interactions.

Moclobemide may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Headache: transient cranial pain. - Dizziness: sensation of light‑headedness. - Insomnia: difficulty initiating or maintaining sleep. - Dry mouth: reduced salivation. - Fatigue: generalized tiredness.

Serious or Rare Side Effects: - Hypertensive crisis: sudden severe elevation of blood pressure, especially with tyramine‑rich foods. - Serotonin syndrome: symptoms such as agitation, hyperthermia, and neuromuscular abnormalities. - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe skin reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hematologic abnormalities: neutropenia or agranulocytosis. - Psychosis: emergence of hallucinations or delusional thinking.

When prescribing Moclobemide, clinicians should observe several precautionary measures to minimize risks. - Avoid tyramine-rich foods: limit intake of aged cheeses, cured meats, and certain alcoholic beverages. - Monitor blood pressure: check for signs of hypertensive episodes, especially during dietary changes. - Assess liver function: perform baseline and periodic liver enzyme tests. - Evaluate for serotonin‑synergistic drugs: avoid concurrent use with SSRIs, SNRIs, or tramadol. - Counsel on alcohol use: advise patients to limit alcohol consumption to reduce interaction risk. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Moclobemide interacts with several medicines; understanding the interaction level guides clinical decisions.

Major Interactions (Avoid): - SSRIs and SNRIs: risk of serotonin syndrome. - Tramadol: potentiates serotonergic effects. - Tyramine-rich foods combined with sympathomimetic agents: may cause hypertensive crisis.

Moderate Interactions (Monitor Closely): - Other MAO inhibitors: additive inhibition. - Certain antipsychotics (e.g., clozapine): may raise plasma levels. - Warfarin: possible alteration of anticoagulant effect.